Liquid chromatography–tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma
- 5 March 2007
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 21 (6) , 621-627
- https://doi.org/10.1002/bmc.797
Abstract
A liquid chromatography–tandem mass spectrometric assay for the determination of the antiretroviral nucleoside emtricitabine in human plasma was developed and validated using a simple sample pre‐treatment procedure. After addition of 5′‐deoxy‐5‐fluorocytidine as the internal standard and protein precipitation with acetonitrile, the supernatant was directly injected in the isocratic chromatographic system using a polar embedded reversed‐phase column and formic acid in water–methanol as the eluent. The eluate was completely led into an electrospray interface with positive ionization and the analytes were quantified using triple quadrupole mass spectrometry. The assay was validated in the range 5–5000 ng/mL. Intra‐day precisions were ≤7% and inter‐day precisions were ≤10%. Accuracies between 92 and 99% were found. The analytes were chemically stable under all relevant conditions and the assay was applied in the analysis of plasma samples of HIV‐infected patients treated with the drug. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Determination of anti-HIV drug concentration in human plasma by MALDI-TOF/TOFJournal of Chromatography B, 2006
- Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatographyJournal of Chromatography B, 2006
- Efavirenz/Emtricitabine/Tenofovir Disoproxil FumarateDrugs, 2006
- Emtricitabine, a New Antiretroviral Agent with Activity against HIV and Hepatitis B VirusClinical Infectious Diseases, 2006
- Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extractionJournal of Chromatography B, 2005
- Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV InfectionAIDS Research and Human Retroviruses, 2004
- Emtricitabine: A Once-Daily Nucleoside Reverse Transcriptase InhibitorAnnals of Pharmacotherapy, 2004
- Pharmacokinetics and Safety of Single Oral Doses of Emtricitabine in Human Immunodeficiency Virus-Infected ChildrenAntimicrobial Agents and Chemotherapy, 2004
- Dose Range Study of Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults with Hepatitis B Virus InfectionAntimicrobial Agents and Chemotherapy, 2002
- High-performance liquid chromatography of HIV protease inhibitors in human biological matricesJournal of Chromatography B: Biomedical Sciences and Applications, 2001